The European Society for Medical Oncology (ESMO) posted on X/Twitter:
“ESMO Guideline: Oncogene-Addicted mNSCLC. Developed due 2 advances in biomarker identification and targeted therapies; updated recommendations and treatment algorithms on new and clinically relevant biomarker identification, targeting and advanced disease management.”
View additional information.
Source: The European Society for Medical Oncology (ESMO)/X